Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

23ANDME HOLDING CO.

(ME)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

23andMe : Researchers identify genes associated with longer reproductive lifespan in women

08/04/2021 | 03:57pm EDT

New Insight for Women

Beyond a better understanding of the genetic influences for extending reproductive health, the study also offers insights into identifying which women might reach menopause earlier than other s. This in turn could help those women decide on the timing of when or if to have children.

'We can start to predict which women might have an earlier menopause and therefore struggle to get pregnant naturally. And because we are born with our genetic variations, we could offer this advice to young women,' said Dr. Katherine Ruth, of the University of Exeter, and a study co-author.

More Delaying Having Children

While life expectancy has dramatically gone up over the last century or more, the age at which women enter menopause - around 50 - has not changed. Women are born with all the eggs they will ever carry, and these are gradually lost with age. Menopause occurs once most of a woman's eggs are gone, although fertility declines substantially before that time, making it much more difficult for some women to get pregnant. There are a number of factors playing into the delay in having children, including financial and career considerations. According tonewly released datafrom the Centers for Disease Control and Prevention, the COVID-19 pandemic resulted in the sharpest drop in childbirth in more than a century.

Many of the genes the study identified are associated with the process of DNA repair and are active before birth when human eggs are created and stored. These include the genes CHEK1and CHEK2, which regulate a broad variety of DNA repair processes.

'We saw that two of the genes which produce proteins involved in repairing damaged DNA work in opposite ways with respect to reproduction in mice,' said Professor Ignasi Roig, of the Autonomous University of Barcelona and another of the study's co-authors.

The researchers found that turning off the function of the gene CHEK2, while enhancing the expression of CHEK1, extended the reproductive lifespan of mice by about 25 percent. The study also looked at women who naturally lack an active CHEK2gene, and found that these women reach menopause on average 3.5 years later than women with a normally active gene.

For this study on reproductive lifespan, the researchers relied on a global collaboration involving more than 180 academic institutions and data from hundreds of thousands of women including 300,000 female customers from 23andMe who consented to participate in research. The researchers also included data from theUK Biobankand several other study cohorts. While most of the de-identified and aggregated data was from women of European ancestry, the researchers also looked at data from women of East Asian ancestry.

Menopause

The team discovered that many of the genes involved are linked to processes of DNA repair. They also found that many of these genes are active from before birth, when human egg stores are created, but also throughout life as well. Notable examples are genes from Female mice with more of the CHEK1 protein are born with more eggs and they take longer to deplete naturally, so reproductive lifespan is extended. The second gene, CHEK2, has a similar effect, allowing eggs to survive longer, but in this case, the gene has been knocked out so that no protein is produced.'

The team also examined the health impacts of having an earlier or later menopause by using an approach that tests the effect of naturally occurring genetic differences. They found that genetically earlier menopause increases the risk of type 2 diabetes and is linked to poorer bone health and increased risk of fractures. However, it decreases the risk of some types of cancer, such as ovarian and breast cancer, that are known to be sensitive to sex hormones which are at higher levels while a woman is still menstruating.

Disclaimer

23Andme Holding Co. published this content on 04 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 August 2021 19:56:06 UTC.


ę Publicnow 2021
All news about 23ANDME HOLDING CO.
09/1723ANDME : Offers Revelations for Adoptee Searching for His Siblings
PU
09/1523ANDME : Taking Control for a Healthier Pregnancy
PU
09/1423ANDME : Talking About Rare Disease with Senior Scientist Suyash Shringarpure
PU
09/1023ANDME : Investor Presentation, dated September 2021 (Form 8-K)
PU
09/1023ANDME HOLDING CO. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-..
AQ
09/0823ANDME : Raising Awareness About Fatty Liver Disease
PU
09/0123ANDME : to Present at the Wells Fargo Healthcare Conference
AQ
08/2623ANDME : Felt Ill After COVID-19 Vaccine? It May Depend on Which Vaccine and Whether You'..
PU
08/2423ANDME : The Genetics of Loving or Hating Marmite
PU
08/1823ANDME : Looks at Data on E-Cigarette Use
PU
More news
Analyst Recommendations on 23ANDME HOLDING CO.
More recommendations
Financials (USD)
Sales 2022 257 M - -
Net income 2022 -213 M - -
Net cash 2022 536 M - -
P/E ratio 2022 -15,3x
Yield 2022 -
Capitalization 3 539 M 3 539 M -
EV / Sales 2022 11,7x
EV / Sales 2023 10,0x
Nbr of Employees 500
Free-Float 22,1%
Chart 23ANDME HOLDING CO.
Duration : Period :
23andMe Holding Co. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends 23ANDME HOLDING CO.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 8,70 $
Average target price 12,50 $
Spread / Average Target 43,7%
EPS Revisions
Managers and Directors
Anne E. Wojcicki Chief Executive Officer & Director
Steven Schoch Chief Financial & Accounting Officer
Steve Lemon Vice President-Engineering
Joyce Tung Vice President-Research
L. Okey Onyejekwe VP-Healthcare Operations & Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
23ANDME HOLDING CO.-23.88%3 539
SONIC HEALTHCARE LIMITED29.24%14 499
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.-24.16%6 952
NEOGENOMICS, INC.-12.70%5 780
DR. LAL PATHLABS LIMITED71.40%4 422
HEALIUS LIMITED32.17%2 159